- Bachelor in Physiology & Cell Biology, University of Rennes I (France) – 1988.
- Master in Molecular & Cell Biology, University Blaise Pascal, Clermont-Ferrand (France) – 1990.
- Ph.D. in Molecular & Cell Biology (Immunology), College of Agriculture of Rennes (France) – 1994.
- The Research projects ongoing in Dr. Dréau’s laboratory focus on understanding the molecular, cellular, and physiological bases of metastases associated with cancers of epithelial origin.
- The cancers of epithelial origin include: the most lethal skin cancer, i.e. melanoma and the most common solid tumor in female i.e., breast cancer. In these cancers as in others, the occurrence of metastases is associated with a high mortality (see the site of the American Cancer Society for details on cancer statistics in the US: http://www.cancer.org)
- The development of metastases is a multi-step process, which, from the tumor standpoint, includes:
- Development of tumor cells with metastatic potentials.
- Detachment, migration of tumor cells generally through the vascular system (blood, lymph vessels), and anchoring within the host tissue.
- Growth of the metastatic mass requiring the concurrent development of vessels, i.e. neo-angiogenesis, which provide oxygen and various nutriments.
- Preventing responses of the immune system throughout all the steps associated with the development of tumor metastases.
Dr. Dréau’s research centers on the mechanisms of cancer metastasis, and the vascular and immune interactions associated with cancer growth. More specifically, the following aspects of cancer metastasis are studied:
- Key features of Metastatic Tumors
- Anchoring and Growth of Metastatic Tumors
- Vascularization of the Metastatic Tumors
- Interactions Immune System and Metastases
- Potential Graduate Students (Ph.D. or M.S.) should contact Dr. Didier Dréau at: email@example.com
- For REU opportunities please check the REU Summer Program: Biology and Biotechnology at http://biology.uncc.edu/research/reu-biotechnology
- Potential UnderGraduate Students (BIOL3900) should contact Dr. Didier Dréau at: firstname.lastname@example.org
- Donna Goodenow (PhD Student)
- Bryanna Sierra (UG student)
- Postdoctoral Fellows
– Muthulekha Swamydas, PhD (2008-2010)
– Danielle Van, PhD (2011-2012)
- Graduate students
– Rachel S. Helms, MS (2015). Macrophages Expressing Neuropilin-1 and Breast Tumor Progression. UNC Charlotte
– Michelle M. Phelps, PhD (2015). Periostin and TGFBI in Breast Cancer Progression” UNC Charlotte
– Yas Maghdouri-White, PhD (2014). “Mammary Epithelial Cells Cultured onto Non-Woven Nanofiber Electrospun Silk-Based Biomaterials to Engineer Beast Tissue Models“. Virginia Commonwealth University.
– Stephen L. Rego, PhD (2013). “Factors Shed by Breast Tumor Cells, Tumor Necrosis Factor alpha Converting Enzyme Activities and the Generation of Pro-Tumor Macrophages” UNC Charlotte
– Anindita Das Burman MS (2013). “TGF-β (beta) and Periostin Modulate each others Expressions in both Breast Stroma and Cancer Cells” Skovde University, Sweden
– Krista Ricci, MS (2012). “Hypoxia and Breast Cell Migration” UNC Charlotte
– Adam Secret, MS (2010). “Breast Cancer Cell Responses to TGFß are Affected by Hypoxia and the Extracellular Matrix” UNC Charlotte
– Ashley Jewell, MS thesis (2010). “Endothelin-1, Inflammatory Cytokines, and Macrophages in Breast Cancer” UNC Charlotte
– Andrew Cox, MS (2008). “Hypoxia, Vascular Endothelial Growth Factor, and Endothelin in Human Breast Cancer” UNC Charlotte
- Honors Undergraduate students
– Kerri Ann McDermott (2005-2006)
– Do (Jason) Nguyen (2006-2007)
– Hebah Sadek (2007-2008)
– Alim Hamid (2008-2009)
– Amber Lathom Yow (2009-2010)
– Ashley Brooker (2011-2012)
– Ronald Valencia (2011-2012)
– Alexander de Piante (2012)
– Rachel Helms (2012-2013)
– Thany Seyok (2014-2015)
- Rego SL, Helms RS, Dréau D.Breast tumor cell TACE-shed MCSF promotes pro-angiogenic macrophages through NF-κB signaling.Angiogenesis. 2013 Nov 7. [Epub ahead of print]
- Rego SL, Helms RS, Dréau D., 2013. Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer. Immunol Res. 2013 Sep 27. [Epub ahead of print]
- Nieman DC, Luo B, Dréau D, Henson DA, Shanely RA, Dew D, Meaney MP., 2013. Immune and inflammation responses to a 3-day period of intensified running versus cycling. Brain Behav Immun. 2013 Sep 19. doi:pii: S0889-1591(13)00458-3. 10.1016/j.bbi.2013.09.004. [Epub ahead of print]
- Maghdouri-White Y, Elmore LW, Bowlin GL, Dréau D., 2013. Breast epithelial cell infiltration in enhanced electrospun silk scaffolds. J Tissue Eng Regen Med. 2013 Jun 24. doi: 10.1002/term.1778. [Epub ahead of print]
- Rego SL, Swamydas M, Kidiyoor A, Helms R, De Piante A, Lance AL, Mukherjee P, Dréau D., 2013.Soluble Tumor Necrosis Factor Receptors Shed by Breast Tumor Cells Inhibit Macrophage Chemotaxis. J Interferon Cytokine Res. 2013 Jun 18. [Epub ahead of print]
- Swamydas M, Ricci K, Rego SL, Dréau D., 2013. Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases. Cell Adh Migr. 2013 May-Jun;7(3):315-24. doi: 10.4161/cam.25138. Epub 2013 May 24.
- Lance A, Yang CC, Swamydas M, Dean D, Deitch S, Burg KJ, Dréau D., 2013. Increased extracellular matrix density decreases MCF10A breast cell acinus formation in 3D culture conditions. J Tissue Eng Regen Med. 2013 Feb 12. doi: 10.1002/term.1675. [Epub ahead of print]
- Carlson J, Baxter SA, Dréau D, Nesmelova IV., 2013. The heterodimerization of platelet-derived chemokines. Biochim Biophys Acta. 2013 Jan;1834(1):158-68. doi: 10.1016/j.bbapap.2012.09.010. Epub 2012 Sep 23.
- Bland E, Dréau D, Burg KJ., 2013. Overcoming hypoxia to improve tissue-engineering approaches to regenerative medicine. J Tissue Eng Regen Med. 2013 Jul;7(7):505-14. doi: 10.1002/term.540. Epub 2012 Jul 4.
- Swamydas M, Nguyen D, Allen LD, Eddy J, Dréau D., 2010. Progranulin stimulated by LPA promotes the migration of aggressive breast cancer cells. Cell Commun Adhes. 2011 Dec;18(6):119-30. Epub 2011 Dec 19.
- Swamydas M, Eddy JM, Burg KJ, Dréau D., 2010. Matrix compositions and the development of breast acini and ducts in 3D cultures. In Vitro Cell Dev Biol Anim. 2010 Sep;46(8):673-84. Epub 2010 Jun 29.
- Dréau D, Karaa A, Culberson C, Wyan H, McKillop IH, Clemens MG., 2006. Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis. Clin Exp Metastasis. 2006;23(1):41-53. Epub 2006 Jul 7.
- Carbonell AM, Matthews BD, Dréau D, Foster M, Austin CE, Kercher KW, Sing RF, Heniford BT., 2004. The susceptibility of prosthetic biomaterials to infection. Surg Endosc. 2005 Mar;19(3):430-5. Epub 2004 Dec 9.
- Brar SS, Grigg C, Wilson KS, Holder WD Jr, Dreau D, Austin C, Foster M, Ghio AJ, Whorton AR, Stowell GW, Whittall LB, Whittle RR, White DP, Kennedy TP., 2004. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther. 2004 Sep;3(9):1049-60.
BIOL 4171/5171 Cell Physiology
BIOL 3273 Animal Physiology
BIOL 2000 UG experience EFRi-REM program (not currently taught)
BIOL 6000/8000 Special Topics in Cancer Biology: Initiation to Metastasis
BIOL4600 Senior Seminar
BIOL 6273 Adv. Human Physiology
BIOL 6143 Integrated Physiology
- 1994-1996 Research Fellowship in Infection and Immunology, Carolinas Medical Center, Charlotte.
- 1996-1997 Research Fellowship in Cancer Immunology, Carolinas Medical Center, Charlotte.
- 1998-2002 Research scientist Dept General Surgery, Carolinas Medical Center, Charlotte.
- 2002-2002 Director of Immunology & Oncology Research, Carolinas Medical Center, Charlotte.
- 2003-2004 Research scientist Department of Biology, University of North Carolina at Charlotte.
- 2004-2010 Assistant Professor, Department of Biology, University of North Carolina at Charlotte.
- 2010-Present Associate Professor, Department of Biology, University of North Carolina at Charlotte.